LDS/Medical Tests/Burkitt Lymphoma Genetic Testing, FISH, Tissue

Burkitt Lymphoma Genetic Testing, FISH, Tissue

Burkitt lymphoma (BL) is a B-cell lymphoma with characteristic histologic and cytologic features that often presents in extranodal sites. It shares certain morphologic and immunotypic features with a process that presents as an acute leukemia. Three clinical variants are recognized: endemic Burkitt lymphoma; sporadic Burkitt lymphoma; and immunodeficiency-associated Burkitt lymphoma. Endemic BL occurs most often in equatorial Africa and New Guinea, where it is a common childhood malignancy. Sporadic BL is seen throughout the world, most often in children and young adults. Immunodeficiency-associated BL is mainly associated with Human Immunodeficiency Virus (HIV) infection, often in patients with acquired immunodeficiency syndrome (AIDS). Prevalence of endemic BL is < 0.2 / 100,000 / year, whereas sporadic BL has an incidence of 1-2% of lymphomas in North America and Europe. BL accounts for 30-50% of childhood lymphomas. Endemic BL is mostly associated with Epstein-Barr virus (EBV) infection. All forms of BL show one of several translocations involving the gene *c-myc*, which are highly characteristic but not entirely specific for the disease. As a result of these translocations, *c-myc* expression is deregulated, driving tumor cells through the cell cycle and activating target genes involved in the apoptotic pathway. BL tumor cells remain in a near constant state of division, leading to a highly aggressive, fast growing malignancy that is nonetheless potentially curable. Most BL cases have *c-myc* translocation at band 8q24 to the Immunoglobulin heavy chain region 14q32 [t(8;14)]or, less commonly, to the lambda 22q11 [t(8;22)]or kappa 2p12 [t(8;2)]light chain loci. C-myc t(8;14) (q24.1;q32) is seen in 80% of cases. The remaining two translocations, t(8;22) and t(2;8), have been demonstrated in the remaining 20% of cases. However, up to 10% of BL cases may lack a demonstrable *c-myc* translocation by FISH, a finding that is not well understood. Since BL has one of the fastest doubling times (the time it takes to double the number of cells) it is extremely sensitive to chemotherapy. Fluorescence in situ hybridization (FISH) for the *c-myc* translocation has a very high sensitivity and specificity for BL diagnosis in inconclusive routine cases. The tumors typically express B cell associated markers CD19, CD20 and CD22, in addition to CD10 and BCL6. The fast doubling time is reflected in its typically staining almost 100% of its cells for the proliferation marker Ki67 (MIB1). In addition, these tumors often show TCF3 and ID3 gene mutations involved in a very powerful cell survival pathway that appears to be unique to BL. Other genetic testing can be used for detection of these translocations.
  • Diagnosis of Burkitt lymphoma
  • Management of Burkitt lymphoma (therapy treatment and disease management)
  • Rule out Burkitt lymphoma from other similar symptomatic lymphomas and leukemis

At least 200 interphase cells will be counted for each sample. Dual fusion pattern at or greater than 3% is considered positive for t(8;14)(q24;q32). Break-apart pattern at or greater than 5% is considered positive for an (8q24) rearrangement.

Increased in (detected):

  • Endemic Burkitt lymphoma
  • Sporadic Burkitt lymphoma
  • Immunodeficiency-associated Burkitt lymphoma

The critical point in the diagnosis of BL is the distinction between BL and diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin’s lymphoma in adults, as the treatment of these two diseases differs.

Negative for translocations

Less than 3% dual fusion pattern for t(8;14)(q24;q32), and less than 5% break-apart pattern for an (8q 24) rearrangement.

 

 

Fluorescent In Situ Hybridization (FISH), Real-time PCR using specific probes for translocations, PCR with chip array technology, Flow Cytometry Gene expression profiling microarrays have shown promising results in this field.

Paraffin-embedded, formalin-fixed tissue block.

Specimen Stability

Paraffin-embedded formalin fixed tissue:

  • Ambient: indefinitely

 

EBV serology, EBV by PCR, Chromosomal analysis by cytogenetic, Comparative Genomic Hybridization.
3-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login